Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

<< Previous

Bullboard Posts

Next >>

Post by shareswapperon Apr 09, 2020 1:12pm

404 Views

Post# 30894784

Alexion Knows Bertilimumab Is a Winner

That's why they snagged the rights from Immune in the first place. There are many potential indications for this drug and Alexion will not want ICO having the Occular aspects. They need to buy ICO out to secure 100% and on top of that they know they will get a winner in Amp B, which is a low cost "no brainer". Watch for M&A here, pretty sure it's in the works.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"